Horizon Will Submit Krystexxa sBLA To Strengthen Clinical Profile In Gout
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.
You may also be interested in...
Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
Horizon Makes The Case For An Ambitious $10Bn Sales Goal
The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.
Horizon And Arrowhead To Develop RNAi Therapeutic For Gout
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.